Mission to scale organization to meet the accelerating demand for NO2 sterilization Noxilizer’s Board of Directors announces the appointment of Christopher A. Thatcher as President & CEO effective May 13. He has also joined the Board of Directors. Chris brings a proven track record of experience in early-stage private and publicly held medical device companies,
Noxilizer appoints Christopher A. Thatcher as new CEO Read More »
Demand for NO2 sterilization grows and new facility is booked through 2024 Noxilizer announces the availability of NO2 contract sterilization in the United States at their Hanover, MD headquarters. This facility is conveniently located next to the Baltimore Washington International Airport and in close proximity to global pharmaceutical companies and some of the leading contract
Noxilizer expands NO2 contract sterilization in the United States Read More »
Noxilizer announces that multiple pharmaceutical and biotech companies have completed or are in the process of completing sterilization validation of products that will be submitted to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) starting in early 2023. This marks further advancement in the adoption of nitrogen dioxide (NO₂) sterilization. NO₂ sterilization is rapidly